መነሻIMMP • NASDAQ
add
Immutep Ltd - ADR
የቀዳሚ መዝጊያ
$1.99
የቀን ክልል
$1.96 - $2.02
የዓመት ክልል
$1.58 - $3.34
የገበያው አጠቃላይ ዋጋ
295.73 ሚ USD
አማካይ መጠን
118.96 ሺ
ዜና ላይ
ፋይናንስ
የገቢ መግለጫ
ገቢ
የተጣራ ገቢ
| (AUD) | ጁን 2024info | ከዓመት ዓመት ለውጥ |
|---|---|---|
ገቢ | 865.57 ሺ | -4.89% |
የሥራ ወጪ | 2.03 ሚ | -10.92% |
የተጣራ ገቢ | -10.74 ሚ | -11.49% |
የተጣራ የትርፍ ክልል | -1.24 ሺ | -17.23% |
ገቢ በሼር | — | — |
EBITDA | -11.21 ሚ | -17.52% |
ውጤታማ የግብር ተመን | — | — |
ቀሪ ሒሳብ ሉሆች
አጠቃላይ ንብረቶች
አጠቃላይ ተጠያቂነቶች
| (AUD) | ጁን 2024info | ከዓመት ዓመት ለውጥ |
|---|---|---|
ጥሬ ገንዘብና የአጭር ጊዜ መዋዕለ ንዋይ | 181.88 ሚ | 47.37% |
አጠቃላይ ንብረቶች | 201.58 ሚ | 36.71% |
አጠቃላይ ተጠያቂነቶች | 12.06 ሚ | 9.82% |
አጠቃላይ እሴት | 189.52 ሚ | — |
የሼሮቹ ብዛት | 1.45 ቢ | — |
የገበያ ዋጋ እና የተገለጸ ዋጋ | 15.31 | — |
የእሴቶች ተመላሽ | -14.53% | — |
የካፒታል ተመላሽ | -15.32% | — |
የገንዘብ ፍሰት
የተጣራ ዝርዝር ገንዘብ በጥሬ ገንዘብ
| (AUD) | ጁን 2024info | ከዓመት ዓመት ለውጥ |
|---|---|---|
የተጣራ ገቢ | -10.74 ሚ | -11.49% |
ከክወናዎች የተገኘ ጥሬ ገንዘብ | -8.19 ሚ | 30.16% |
ገንዘብ ከኢንቨስትመንት | -10.30 ሚ | -87,445.92% |
ገንዘብ ከፋይናንስ | 47.81 ሚ | 25.58% |
የተጣራ ዝርዝር ገንዘብ በጥሬ ገንዘብ | 29.03 ሚ | 5.47% |
ነፃ የገንዘብ ፍሰት | -6.10 ሚ | -44.31% |
ስለ
Immutep Ltd is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.
Prima currently has three main products in its pipeline, all acquired with Immutep:
Eftilagimod alpha, which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer.
IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline.
IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis Wikipedia
ዋና ሥራ አስፈጻሚ
የተመሰረተው
2001
ድህረገፅ
ሠራተኞች
19
